|37.69||-2.89||-7.12%||Vol 133.49K||1Y Perf -5.78%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||60.00||Analyst Rating||— — 0.00|
|Potential %||59.19||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||1.01B||Earnings Rating||—|
|Price Range Ratio 52W %||17.48||Earnings Date||-|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||67.67K|
|Avg. Monthly Volume||205.93K|
|Avg. Quarterly Volume||163.27K|
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) stock closed at 37.69 per share at the end of the most recent trading day (a -7.12% change compared to the prior day closing price) with a volume of 133.49K shares and market capitalization of 1.01B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. 4D Molecular Therapeutics Inc. CEO is David Kirn.
The one-year performance of 4D Molecular Therapeutics Inc. stock is -5.78%, while year-to-date (YTD) performance is %. FDMT stock has a five-year performance of %. Its 52-week range is between 34 and 55.11, which gives FDMT stock a 52-week price range ratio of 17.48%
4D Molecular Therapeutics Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 4.52, a price-to-sale (PS) ratio of 81.17, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.72%, a ROC of -75.01% and a ROE of -61.82%. The company’s profit margin is -%, its EBITDA margin is -307.70%, and its revenue ttm is $13.61 Million , which makes it $0.51 revenue per share.
Of the last four earnings reports from 4D Molecular Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. 4D Molecular Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for 4D Molecular Therapeutics Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for 4D Molecular Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
4D Molecular Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
4D Molecular Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ATR14 : 2.30, Money Flow Index : 48.89, ROC : 10.53, RSI : 55.01, STOCH (14,3) : 93.03, STOCH RSI : 1.00, Williams %R : -6.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of 4D Molecular Therapeutics Inc. in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.